A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.

Clinical trial NCT07619066 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07619066
Sponsor: MedSIR
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Advanced Breast Cancer Hormone Receptor Positive / HER2-negative Breast Cancer HER2 Mutation

Start date: 2026-10-04
Primary completion: 2028-09-28
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.